Pharma Q1 Growth to be Driven by Domestic Formulations, Chronic Therapies, and Biosimilars
Pharma Q1 growth is expected to be driven by domestic formulations, chronic therapies, and biosimilars, while US generics remain a drag on revenue. Companies like Sun Pharmaceutical Industries, Aurobindo Pharma, Lupin, and Torrent Pharmaceuticals are expected to report strong growth in Q1.